TY - JOUR T1 - Development of an Oncolytic Recombinant Vesicular Stomatitis Virus Encoding a Tumor-suppressor MicroRNA JF - Anticancer Research JO - Anticancer Res SP - 6319 LP - 6325 DO - 10.21873/anticanres.14652 VL - 40 IS - 11 AU - TOMOHIKO SAKUDA AU - TADAHIKO KUBO AU - MUHAMMAD PHETRUS JOHAN AU - TAISUKE FURUTA AU - TAKEMASA SAKAGUCHI AU - NOBUO ADACHI Y1 - 2020/11/01 UR - http://ar.iiarjournals.org/content/40/11/6319.abstract N2 - Background: Attempts have been made to enhance systemic therapy for osteosarcoma. In our previous study, the systemic administration of a vesicular stomatitis virus (VSV) improved the survival rates of mice with osteosarcoma but did not improve the long-term survival of the animals. Materials and Methods: In the present study, we developed a novel oncolytic VSV by incorporating tumor-suppressor microRNA143 (rVSV-miR143) to compare the antitumor effects of various doses (10×10−4, 5×10−4, and 1×10−4 multiplicity of infection) of rVSV-miR143 with those of VSV in vitro. Results: The cytotoxicity and migration-inhibitory effects of rVSV-miR143 on the osteosarcoma cells were significantly higher than those of VSV alone at a dose of 5×10−4 multiplicity of infection, indicating that rVSV-miRNA143 enhances the antitumor effect at certain doses. Conclusion: VSV incorporating tumor-suppressor miRNA143 demonstrated a synergistic antitumor effect on osteosarcoma cells in vitro. ER -